Skip to content

US · NGNE · BIOTECHNOLOGY

Neurogene Inc. (NGNE) intrinsic value and stock valuation

$22.15as of 2026-11-21 · Mkt cap 568.57M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Neurogene Inc. DCF and intrinsic value

InvestorsCraft values NGNE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NGNE’s statements →

Neurogene Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10011 neurogene.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-90.35M
20112025
Free cash flow
-$-78.36M
20112025
Total equity
$264.9M+6.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$930K$0.00$0.00$0.00
Operating income-$-103.21M-$-82.61M-$-55.58M-$-56.52M-$-50.53M
Net income-$-90.35M-$-75.14M-$-36.32M-$-55.19M-$-50.52M
EPSd-$-4.27M-$-4.28M-$-2.83M-$-4.3M-$-917.88K
Operating cash flow-$-77.17M-$-70.6M-$-51.42M-$-52.82M-$-46.4M
Capital expenditure-$-1.18M-$-810K-$-320K-$-2.23M-$-18.37M
Free cash flow-$-78.36M-$-71.41M-$-51.74M-$-55.05M-$-64.77M
Total assets$288.6M$335.7M$222.6M$109.3M$101.5M
Total debt$9.89M$12.4M$16.3M$4.69M$6.43M
Net debt-$-93.95M-$-124.16M-$-131.96M-$-77.33M-$-64.11M
Total equity$264.9M$310.4M$186M$98.6M-$-91.88M
Cash and short-term investments$269M$312.4M$197.2M$82M$70.5M
Income statement
20252024202320222021
Revenue$0.00$930K$0.00$0.00$0.00
Cost of revenue$3.19M$3.25M$3.26M$3.2M$42.3M
Gross profit-$-3.19M-$-2.32M-$-3.26M-$-3.2M-$-42.26M
Research and development expenses$75M$60.9M$44.4M$47.5M$42.3M
Selling, general and administrative expenses$25.1M$22.6M$11.2M$9.01M$8.27M
Other expenses$0.00-$-3.25M-$-3.26M-$-3.2M-$-42.26M
Operating expenses$100M$80.3M$52.3M$53.3M$8.27M
Cost and expenses$103.2M$83.5M$55.6M$56.5M$50.5M
Interest income$11.6M$8.47M$2.95M$1.34M$20K
Interest expense$10K$10K$10K$0.00$0.00
Depreciation and amortization$3.09M$3.25M$3.3M$3.2M$950K
Ebitda-$-87.25M-$-71.89M-$-33.01M-$-51.99M-$-49.57M
Operating income-$-103.21M-$-82.61M-$-55.58M-$-56.52M-$-50.53M
Total other income/expenses, net$12.9M$7.46M$19.3M$1.33M$20K
Income before tax-$-90.35M-$-75.14M-$-36.32M-$-55.19M-$-50.52M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-90.35M-$-75.14M-$-36.32M-$-55.19M-$-50.52M
Weighted average shares outstanding$21.2M$17.6M$12.8M$12.8M$55M
Weighted average diluted shares outstanding$21.2M$17.6M$12.8M$12.8M$55M
Balance sheet
20252024202320222021
Cash and short-term investments$269M$312.4M$197.2M$82M$70.5M
Net receivables$0.00$650K$600K$0.00$790K
Inventory$0.00$0.00$0.00$0.00$1.91M
Total current assets$271.8M$315.9M$200.4M$84.7M$74M
Property, plant and equipment, net$15.5M$18.5M$21M$24.6M$27.5M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$130K
Long-term investments$0.00$0.00$0.00$0.00$880K
Total non-current assets$16.8M$19.8M$22.2M$24.6M$27.5M
Total assets$288.6M$335.7M$222.6M$109.3M$101.5M
Accounts payable$1.95M$1.34M$2.6M$620K$5.63M
Short-term debt$3.06M$3M$2.88M$700K$1.83M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$16.4M$15.2M$23M$6.65M$10.9M
Long-term debt$6.83M$9.43M$13.4M$3.99M$4.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$7.31M$10.2M$13.6M$3.99M$182.5M
Capital lease obligations$0.00$9.43M$16.3M$4.69M$5.21M
Total liabilities$23.7M$25.4M$36.6M$10.6M$193.4M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-352.65M-$-262.3M-$-187.15M-$-150.84M-$-95.65M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$264.9M$310.4M$186M$98.6M-$-91.88M
Total investments$165.2M$175.8M$49M$0.00$880K
Total debt$9.89M$12.4M$16.3M$4.69M$6.43M
Net debt-$-93.95M-$-124.16M-$-131.96M-$-77.33M-$-64.11M
Cash flow statement
20252024202320222021
Net income-$-90.35M-$-75.14M-$-36.32M-$-55.19M-$-50.52M
Depreciation and amortization$3.09M$3.25M$3.3M$3.2M$950K
Stock-based compensation$14.2M$8.32M$1.42M$1.25M$900K
Change in working capital$270K-$-5.96M-$-4.02M-$-2.69M$1.59M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$630K-$-80K$670K-$-3.61M$2.98M
Net cash provided by operating activities-$-77.17M-$-70.6M-$-51.42M-$-52.82M-$-46.4M
Investments in property, plant and equipment-$-1.18M-$-810K-$-320K-$-2.23M-$-18.37M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$14M-$-125.26M$25.6M-$-2.23M-$-18.37M
Common stock issued$30.4M$189.6M$92.3M$70K$290K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30.4M$184.1M$92.5M$66.5M$51.1M
Net change in cash-$-32.74M-$-11.79M$66.7M$11.5M-$-13.71M
Cash at end of period$104.2M$136.9M$148.7M$82M$70.5M
Operating cash flow-$-77.17M-$-70.6M-$-51.42M-$-52.82M-$-46.4M
Capital expenditure-$-1.18M-$-810K-$-320K-$-2.23M-$-18.37M
Free cash flow-$-78.36M-$-71.41M-$-51.74M-$-55.05M-$-64.77M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Neurogene Inc.

        Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

        CEO
        Rachel L. McMinn
        Employees
        131
        Beta
        1.96

        Explore

        Frequently asked questions

        What is the intrinsic value of Neurogene Inc. (NGNE)?

        InvestorsCraft does not currently publish an intrinsic value for NGNE. How the IC value is calculated.

        Is NGNE undervalued?

        InvestorsCraft does not publish an undervaluation signal for NGNE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.